Status:
COMPLETED
Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, cisplatin, and dexamethasone, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one...
Detailed Description
OBJECTIVES: * Determine the response rate and maximum response in patients with relapsed or refractory Hodgkin's lymphoma treated with gemcitabine, cisplatin, and dexamethasone. * Determine time to p...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of Hodgkin's lymphoma
- Measurable disease by radiological or clinical findings
- Failed at least 1, but no more than 2, prior standard chemotherapy regimens
- High-dose chemotherapy administered after a chemotherapy course is considered 2 courses
- No evidence of CNS disease
- No history of myelodysplastic syndromes
- PATIENT CHARACTERISTICS:
- Age
- Over 18
- Performance status
- ECOG 0-2
- Life expectancy
- Not specified
- Hematopoietic
- WBC \> 2,000/mm\^3
- Absolute neutrophil count \> 1,500/mm\^3
- Platelet count \> 75,000/mm\^3
- Hemoglobin \> 8.0 g/dL
- Hepatic
- Bilirubin \< 2 times upper limit of normal (ULN)
- AST and ALT \< 5 times ULN
- Renal
- Creatinine \< 1.5 times ULN
- Other
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for 3 months after study participation
- PRIOR CONCURRENT THERAPY:
- Biologic therapy
- Not specified
- Chemotherapy
- See Disease Characteristics
- No prior gemcitabine
- More than 6 months since prior high-dose chemotherapy
- Endocrine therapy
- Not specified
- Radiotherapy
- Not specified
- Surgery
- Not specified
Exclusion
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00090909
Start Date
June 1 2003
Last Update
January 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States, 90095-1678